Endo EBITDA Margin 2023-2025 | NDOI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Endo ebitda margin from 2023 to 2025. Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Endo EBITDA Margin 2023-2025 | NDOI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Endo ebitda margin from 2023 to 2025. Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$81.3B
Zoetis (ZTS)	$67.7B
Daiichi Sankyo, - (DSNKY)	$46.4B
Takeda Pharmaceutical (TAK)	$46.1B
BeOne Medicines - (ONC)	$31.9B
Sandoz Group AG (SDZNY)	$26.1B
Summit Therapeutics (SMMT)	$21.3B
Merck (MKKGY)	$17.2B
Shionogi (SGIOY)	$14.6B
United Therapeutics (UTHR)	$13.7B
Neurocrine Biosciences (NBIX)	$13.1B
Orion OYJ (ORINY)	$11.7B
IPSEN (IPSEY)	$10.9B
Stevanato Group S.p.A (STVN)	$8B
Corcept Therapeutics (CORT)	$7.2B
Grifols, S.A (GRFS)	$6.9B
Ionis Pharmaceuticals (IONS)	$6.7B
Madrigal Pharmaceuticals (MDGL)	$6.6B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.4B
Hypermarcas (HYPMY)	$2.9B
Crinetics Pharmaceuticals (CRNX)	$2.9B
NewAmsterdam Pharma (NAMS)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.1B
Ocular Therapeutix (OCUL)	$1.9B
BioCryst Pharmaceuticals (BCRX)	$1.8B
ARS Pharmaceuticals (SPRY)	$1.8B